Pharma Mar (FRA:PMRA) Operating Margin %: 1.45% (As of Mar. 2026) — 202% Above Median


FRA:PMRA Pharma Mar SA FRA:PMRA
83 GF Score
Price €68.05
GF Value €83.37
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Operating Margin %?

Pharma Mar FRA:PMRA -1.80% 83 Operating Margin % is 1.45% as of Mar. 2026, which is 202% above its 10-year median of 0.48. GuruFocus rates FRA:PMRA with a GF Score™ of 83/100 and a GF Value™ of €83.37 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Pharma Mar ranks better than 89.95% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pharma Mar's Operating Income for the three months ended in Mar. 2026 was €0.6 Mil. Pharma Mar's Revenue for the three months ended in Mar. 2026 was €42.9 Mil. Therefore, Pharma Mar's Operating Margin % for the quarter that ended in Mar. 2026 was 1.45%.

The historical rank and industry rank for Pharma Mar's Operating Margin % or its related term are showing as below:

FRA:PMRA' s Operating Margin % Range Over the Past 10 Years
Min: -20.36   Med: 0.48   Max: 57.86
Current: 22.68


FRA:PMRA's Operating Margin % is ranked better than
89.95% of 945 companies
in the Biotechnology industry
Industry Median: -86.77 vs FRA:PMRA: 22.68

Pharma Mar's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Pharma Mar's Operating Income for the three months ended in Mar. 2026 was €0.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €59.7 Mil.


Pharma Mar  (FRA:PMRA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pharma Mar Operating Margin % Related Terms


Pharma Mar Operating Margin % Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Operating Margin % Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.18 22.63 -2.48 3.44 27.08

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.94 42.83 -11.10 30.30 1.45

FRA:PMRA vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Pharma Mar's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Mar Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Mar's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Pharma Mar's Operating Margin % falls into.


FRA:PMRA
83GF Score
Pharma Mar SA FRA:PMRA
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Pharma Mar's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=59.961 / 221.39
=27.08 %

Pharma Mar's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0.622 / 42.899
=1.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 1.45% mean?
Pharma Mar (FRA:PMRA) has a Operating Margin % of 1.45% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Pharma Mar and its competitors. This is 202% above median its historical median of 0.48. According to the industry distribution chart, Pharma Mar ranks #95 out of 945 companies in the Biotechnology industry, placing it in the top 10.1%.
Is Pharma Mar's Operating Margin % too high?
Pharma Mar's current Operating Margin % of 1.45% is 202% above median its 10-year median of 0.48. Based on the distribution chart, Pharma Mar ranks #95 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #95 out of 945 companies for Operating Margin %. This places Pharma Mar in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Pharma Mar and its competitors. Pharma Mar's current Operating Margin % is 1.45%, which is 202% above median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (FRA:PMRA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.37, compared to a current price of €68.05 — trading 18.4% below its estimated fair value. The current Operating Margin % is 1.45%, which is 202% above median its 10-year median of 0.48. Pharma Mar's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Pharma Mar (FRA:PMRA), the current Operating Margin % is 1.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (FRA:PMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of €68.05 is trading 18.4% below its estimated GF Value™ of €83.37. GuruFocus considers Pharma Mar to be Modestly Undervalued.

Key valuation signals for FRA:PMRA:

  • Operating Margin %: 1.45% (202% above median its 10-year median of 0.48)
  • GF Value™: €83.37 vs. price of €68.05 (18.4% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the FRA:PMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
83GF Score

Get the complete analysis for FRA:PMRA

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.05
Price
€83.37
GF Value